Evidence map›Paper›PMID 37081754›Full record

ArticleCancer medicine2023

Maintenance regimen of GM-CSF with rituximab and lenalidomide improves survival in high-risk B-cell lymphoma by modulating natural killer cells.

Shunrong Sun, Wulipan Fulati, Lin Shen, Min Wu, Zilan Huang, Wensi Qian, Pingping Chen, Yingwei Hu, Mingyue Chen, Yu Xu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shunrong SunDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.ORCID 0000-0001-7636-2639
Wulipan FulatiDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Lin ShenDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Min WuDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Zilan HuangDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Wensi QianDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Pingping ChenDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Yingwei HuDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Mingyue ChenDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Yu XuDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Hongdi ZhangDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Jiexian MaDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Yanhui XieDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe treatment of high-risk B-cell lymphoma (BCL) remains a challenge, especially in the elderly.

methodsA total of 83 patients (median age 65 years), who have achieved a complete response after induction therapy, were divided into two groups: R

resultsThe number of natural killer cells in patients increased after R

conclusionsThe maintenance therapy of R

Indexed as

Granulocyte-Macrophage Colony-Stimulating FactorLymphoma, B-CellAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsHumansKiller Cells, NaturalLenalidomideProspective StudiesRituximabAntibodies, Monoclonal, Murine-DerivedGranulocyte-Macrophage Colony-Stimulating FactorLenalidomideRituximabB-cell lymphomalenalidomidemaintenance therapyrhGM-CSFrituximab

Identifiers

PMID37081754
PMCPMC10315792
OpenAlexW4366602274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.